How cancer cells use sugar molecules to avoid the immune system
Glycosylation and Immune Evasion in Urologic Tumors
This study is looking at how certain sugar molecules on proteins might help urologic tumors hide from the immune system, with the goal of finding new ways to treat cancer and choose the best immunotherapy for patients based on their specific tumor traits.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10658839 on NIH RePORTER |
What this research studies
This research investigates the role of glycosylation, a modification of proteins involving sugar molecules, in helping urologic tumors evade the immune system. By analyzing glycoproteins from cancerous and healthy tissues, the study aims to identify specific sugar-related proteins that may contribute to immune evasion. The findings could lead to new therapies and diagnostic tools that help select patients for immunotherapy based on their unique tumor characteristics. The research employs advanced techniques like glycoproteomics and RNA sequencing to correlate protein changes with gene expression.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma or prostate cancer.
Not a fit: Patients with other types of cancer or those not diagnosed with renal cell carcinoma or prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments and better patient selection for immunotherapies in kidney and prostate cancers.
How similar studies have performed: Previous research has shown promising results in targeting glycosylation for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Pitteri, Sharon — Stanford University
- Study coordinator: Pitteri, Sharon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.